Skip to main content

Table 1 Clinical characteristics and outcome of 27 patients with high-risk neuroblastoma

From: Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy

No. Age
Month
Gender Primary site BM N-MYC amplification Tumor reduction FU Outcome
RE1 RE2 (%)
1 39 F R Y N 80% 94 14 CR
2 28 F R Y Y 53% 63 17 Dead
3 30 M R Y Y 94% 99 12 Dead
4 24 F R Y Y 70% 91 19 CR
5 84 M R Y Y 0% 0 17 PR
6 38 F R Y Y 51% 60 20 PR
7 61 F R Y N 41% 64 16 PR
8 36 M P Y Y 79% 79 18 PR
9 39 F R Y Y 72% 77 18 PR
10 19 F R N N 88% 93 21 PR
11 78 M R Y N 70% 89 25 PR
12 30 M R N Y 47% 82 14 Dead
13 40 F R N N 49% 57 13 PR
14 19 F R N N 63% 50 6 Dead
15 59 F R Y N 86% 99 22 CR
16 49 M P N Y 60% 97 13 Dead
17 39 M R Y N 75% 86 16 PR
18 48 M R Y Y 29% 35 18 PR
19 23 F R Y Y 25% 50 5 Dead
20 54 F R Y N 50% 60 13 PR
21 69 F R Y N 60% 80 14 VGPR
22 41 F R N N 0 22 15 PR
23 101 M P Y N 0 15 20 Stable
24 61 M R Y Y 71% 92 20 CR
25 36 F R Y N 50% 81 19 VGPR
26 15 M R Y N 67% 96 21 CR
27 31 M R Y Y 71% 95 14 Dead
  1. R retroperitoneum and renicapsule, P posterior mediastinum, FU follow up